OCULAR PENETRATION OF TOPICALLY APPLIED NORFLOXACIN 0.3-PERCENT IN THE RABBITS AND IN HUMANS

被引：11

作者：

BRON, AM

PECHINOT, A

GARCHER, C

GUYONNET, G

KAZMIERCZAK, A

机构：

[1] Ophthalmology Department, University of Burgundy, Dijon

[2] Laboratory of Bacteriology, University of Burgundy, Dijon

来源：

JOURNAL OF OCULAR PHARMACOLOGY | 1992年 / 8卷 / 03期

关键词：

D O I：

10.1089/jop.1992.8.241

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The kinetics of topically applied norfloxacin 0.3 percent were studied in rabbit and man. All measurements were performed by high-pressure liquid chromatography. Norfloxacin concentrations were investigated five to 120 minutes in rabbit ocular tissues after instillation of a single drop. In normal eyes, after 30 minutes, mean +/- SEM levels were 14.3 +/- 3.7 mug/g in cornea, 3.3 +/- 0.7 mug/g in conjunctiva, 0.2 +/- 0.1 mug/g in aqueous humor. After removal of the corneal epithelium concentrations were as follows : 84.2 +/- 15.8 mug/g, 7.3 +/- 2.3 mug/g, 8.6 +/- 1.9 mug/g respectively. Penetration in posterior ocular tissues were rather poor. In human eyes, the intracorneal concentrations were assessed in patients being operated on corneal grafts. After instillation of 5 drops, the concentration in cornea was 15.5 +/- 2.1 mug/g. These data show that therapeutic levels of norfloxacin can be achieved in anterior ocular tissues, which may be of help in superficial infections of the eye.

引用

页码：241 / 246

页数：6

共 16 条

[1]

Mader T.H., Maher K.L., Stulting R.D., Gentamicin resistance in staphylococcal corneal ulcers, Cornea, 10, pp. 408-410, (1991)

[2]

Gelender H., Rettich C., Gentamicin resistant pseudomonas aeruginosa corneal ulcer, Cornea, 3, (1984)

[3]

Auckenthaler R., Michea-Hamzehpou R., Pechere J.C., In vitro activity of newer quinolones against aerobic bacteria, J Antimicrob Chemother, 17, pp. 29-39, (1986)

[4]

Gupta S.K., Joshi S., Zhingan S., Topical norfloxacin a new drug for the treatment of Pseudomonas corneal ulcers. An experimental study, Med Sci Res, 17, pp. 767-770, (1989)

[5]

Vajpayee R.B., Gupta S.K., Angra S.K., Munjal A., Topical norfloxacin therapy in pseudomonas corneal ulcération, Cornea, 10, pp. 268-271, (1991)

[6]

Borrmann L.R., Leopold L.H., The potential use of quinolones in future ocular antimicrobial therapy, Am I Ophthalmol, 106, pp. 227-229, (1986)

[7]

Bron A., Talon D., Estavoyer J.M., Cellier T., Delbosc B., Montard M., Ocular distribution of new quinolones, Rev Infect Dis, 11, pp. S1206-S1207, (1989)

[8]

Denis F., Mounier M., Adenis J.P., Etude du passage intraoculaire de la péfloxacine chez rhomme et le lapin (humeur aqueuse et vitré), Path Biol, 35, pp. 772-776, (1987)

[9]

Fern A.I., Sweeney G., Doig M., Lindsay G., Penetration of ciprofloxacin into aqueous humor, Trans Ophthalmol Soc UK, 105, pp. 650-652, (1986)

[10]

Keren G., Alhalel A., Bartov E., Kitzes-Cohen R., Rubinstein E., Segev S., Treister G., The intravitreal penetration of orally administered ciprofloxacin in humans, Invest Ophthalmol Vis Sci, 32, pp. 2388-2392, (1991)

← 1 2 →